Several minimally invasive surgical therapies have been developed for the treatment of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostate Hyperplasia (BPH). The objective was to report an update on these new office-based therapies.
This simple review is based on the data available in the literature on office-based minimally invasive surgical techniques for treating BPH. A PubMed search and narrative review of the data were performed in July 2021. Only articles in French or English were reviewed.
The most studied office-based minimally invasive treatments for BPH are water vapor thermal therapy (Rezum® system, Boston Scientific Corporation, Marlborough, MA), prostatic urethral lift (UroLift® system, NeoTract, Inc., Pleasanton, California, USA) and the Temporarily Implanted Nitinol Device (iTind®, Medi-Tate Ltd, Hadera, Israel). Each treatment appears to provide rapid and lasting improvement in LUTS and quality of life, preservation of sexual and ejaculatory functions, rapid postoperative recovery with a minimal adverse event profile, thus allowing outpatient care. Compared to conventional BPH surgeries, these benefits would be offset by higher retreatment rates and less overall improvement in LUTS.
New minimally invasive therapies are promising options that are well tolerated and preserve sexual and ejaculatory functions in men with BPH. Although standard surgical approaches may be more effective, these benefits are valuable for certain patient populations.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2021 Aug 26 [Epub ahead of print]
Michael Baboudjian, Benjamin Pradere
Service d'urologie et de transplantation rénale, CHU de La Conception, AP-HM, Marseille, France. Electronic address: ., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Autriche.